EP4054712A2 — Ror gamma t inhibitors and topical uses thereof
Assigned to Dermira Inc · Expires 2022-09-14 · 4y expired
What this patent protects
The present disclosure is directed to use of RORγt inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This disclosure is also directed to pharmaceutical compositions comprising an RORγt inhibitor and a pharmaceutically acceptable carrier …
USPTO Abstract
The present disclosure is directed to use of RORγt inhibitors in the treatment of autoimmune disorders, e.g., autoimmune disorders of the skin. This disclosure is also directed to pharmaceutical compositions comprising an RORγt inhibitor and a pharmaceutically acceptable carrier for topical administration.
Drugs covered by this patent
- Veklury (remdesivir) · Gilead Sciences
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.